New obesity pill shows promise in early trial
NCT ID NCT06841445
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 2 study tested an experimental pill called HRS9531 in 166 adults with obesity. Participants took either the drug or a placebo daily for 26 weeks. The main goal was to see how much weight they lost compared to those on placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS9531 tablet
- What this could lead to
- If successful, this could lead to a new oral medication for chronic weight management in people with obesity.
- What could go wrong
- This is a Phase 2 trial with only 166 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MANAGEMENT OF BODY WEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanjing Drum Tower hospital
Nanjing, Jiangsu, 210008, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?